Literature DB >> 11136880

Evidence of cerebral hypoperfusion in scleroderma patients.

M Cutolo1, F Nobili, A Sulli, C Pizzorni, M Briata, F Faelli, P Vitali, G Mariani, F Copello, B Seriolo, C Barone, G Rodriguez.   

Abstract

OBJECTIVES: To investigate regional cerebral blood flow by (99m)Tc-hexamethylpropylenamineoxime (HMPAO) single photon emission computed tomography (SPECT) in a series of 40 patients (mean age 58.5+/-11.5 yr) affected by systemic sclerosis (SSc) in comparison with age-matched healthy controls.
METHODS: Subjects affected by concomitant severe pathologies that might interfere with the interpretation of the SPECT results were excluded. SPECT findings were correlated with the severity of peripheral microvascular involvement, as assessed by nailfold videocapillaroscopy (NVC). Whenever possible, patients underwent magnetic resonance imaging (MRI) of the brain.
RESULTS: Twenty-one SSc patients (52%) showed hypoperfusion in two or more regions of interest (ROIs) at the SPECT analysis. MRI was available in 14 of these patients, and was shown to be altered in eight of them (57%). One patient with both abnormal SPECT and abnormal MRI was affected by mild cognitive impairment. Transcranial Doppler sonography was normal in all but one of these patients with hypoperfusion. Nineteen patients exhibited a normal brain SPECT scan, but the MRI was shown to be altered in 3/12 of them (25%). No significant differences were found between the group of SSc patients showing hypoperfusion and those showing a normal SPECT scan regarding age, the duration of disease, the presence of vascular risk factors or damage of other organs typically involved in the disease, and the severity of peripheral microvascular involvement (NVC).
CONCLUSIONS: Focal or diffuse cerebral hypoperfusion was found in more than half of the neurologically asymptomatic SSc patients studied, paralleling the incidence of altered brain MRI. The hypoperfusion was not linked to ageing and possibly reflects the cerebral location of the microangiopathic process characterizing the disease.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11136880     DOI: 10.1093/rheumatology/39.12.1366

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  14 in total

1.  Neurosonological and cognitive screening for evaluation of systemic sclerosis patients.

Authors:  B R Sakr; R E Rabea; A M Aboulfotooh; N A Kishk
Journal:  Clin Rheumatol       Date:  2019-02-26       Impact factor: 2.980

Review 2.  [Capillaroscopy and rheumatic diseases: state of the art].

Authors:  M Cutolo; A Sulli; M E Secchi; C Pizzorni
Journal:  Z Rheumatol       Date:  2006-07       Impact factor: 1.372

3.  Seizures in systemic sclerosis.

Authors:  Fernando Glasner Araújo; Tiago Nardi Amaral; Simone Appenzeller; Jozélio Freire de Carvalho
Journal:  Rheumatol Int       Date:  2012-12-29       Impact factor: 2.631

Review 4.  Nailfold video-capillaroscopy in systemic sclerosis.

Authors:  M Cutolo; C Pizzorni; A Sulli
Journal:  Z Rheumatol       Date:  2004-12       Impact factor: 1.372

5.  Retinal findings in systemic sclerosis: a comparison with nailfold capillaroscopic patterns.

Authors:  O Ushiyama; K Ushiyama; T Yamada; S Koarada; Y Tada; N Suzuki; A Ohta; K Nagasawa
Journal:  Ann Rheum Dis       Date:  2003-03       Impact factor: 19.103

6.  Systemic sclerosis associated with generalized vasculitis and hypopituitarism.

Authors:  John C Katsantonis; John Protopsaltis; Stelios Kokkoris; Paris Brestas; Kyriaki Aroni; Symeon Tournis; Gregory Giannoulis
Journal:  Rheumatol Int       Date:  2008-04-24       Impact factor: 2.631

7.  Brain MRI screening showing evidences of early central nervous system involvement in patients with systemic sclerosis.

Authors:  Reem Hamdy A Mohammed; Yousriah Y Sabry; Amr A Nasef
Journal:  Rheumatol Int       Date:  2010-01-13       Impact factor: 2.631

Review 8.  Acute cerebral vasculopathy in systemic sclerosis.

Authors:  Benoit Faucher; Brigitte Granel; Francois Nicoli
Journal:  Rheumatol Int       Date:  2012-12-23       Impact factor: 2.631

9.  Cerebellar atrophy in systemic sclerosis.

Authors:  Luís Pinheiro; João Freitas; Margarida Lucas; Rui M M Victorino
Journal:  J R Soc Med       Date:  2004-11       Impact factor: 18.000

10.  Psychiatric manifestations of autoimmune disorders.

Authors:  David B Weiss; Jarl Dyrud; Robert M House; Thomas P Beresford
Journal:  Curr Treat Options Neurol       Date:  2005-09       Impact factor: 3.972

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.